Clinical trials for drugs to stop or slow the progression of dementia have not been successful. A recent study attempted to determine how much influence, if any, genetic and lifestyle factors may have on the development of dementia.
Brain-based devices claim to offer all kinds of enhancements and improvements, but how can consumers interested in such a device separate legitimate science from mere hype?
In the study of addiction and recovery, the question of whether a person who has an addiction to any substance must avoid all other potentially addictive substances has yet to be definitively answered. Alongside it, some argue that those in recovery may simply substitute one addiction for another.
A newly available test offers to provide information about your telomeres, parts of your DNA that are considered markers of aging, but on its own this information is of little value, and you can make beneficial lifestyle changes without paying for a test.
Precision medicine is an approach to fighting certain types of cancer that considers a person’s family history, environment, and health habits, along with genetic testing, to predict which medication will provide the most effective treatment.
People enroll in clinical trials for a variety of reasons. Some hope to try a new or innovative treatment. Others hope to advance knowledge about a disease. If you’re interested in volunteering for a clinical trial, you should understand the type of study you’d be participating in and know the potential risks.
Stories about medical research are often presented in a manner that makes the findings seem more significant than they really are. It is important to approach such stories with a degree of skepticism, and appropriately tempered expectations.
Many people believe that the placebo effect is solely a psychological phenomenon. But for some people, a placebo can have real, measurable therapeutic benefits. The power of the placebo effect is significant enough that it can actually skew study results. Additional research is needed to better understand how to leverage the placebo effect and when doing so might offer real benefits to patients.
Is brain damage an inevitable consequence of American football, an avoidable risk of it, or neither? An editorial published yesterday in the medical journal BMJ poses those provocative questions. Chad Asplund, director of sports medicine at Georgia Regents University, and Thomas Best, professor and chair of sports medicine at Ohio State University, offer an overview of the unresolved connection between playing football and chronic traumatic encephalopathy, a type of gradually worsening brain damage caused by repeated mild brain injuries or concussions. The big question is whether playing football causes chronic traumatic encephalopathy or whether some people who play football already at higher risk for developing it. The Football Players Health Study at Harvard University hopes to provide a solid answer to that and other health issues that affect professional football players.
Every so often, a medical advance comes along that rewrites the script for treating a disease or condition. After today’s announcement of impressive results of a new type of cholesterol-lowering drug, that scenario just might happen in the next few years. The results of three clinical trials presented today at the annual meeting of the American College of Cardiology, and simultaneously published in the New England Journal of Medicine, suggest that a class of new drugs called PCSK9 inhibitors can dramatically reduce the amount of harmful LDL cholesterol circulating in the bloodstream and prevent heart attacks, strokes, and other problems related to cholesterol-clogged arteries. The drawbacks are that PCSK9 inhibitors must be given by injection every 2 to 4 weeks, may cause mental confusion or trouble paying attention, and, if approved, will likely be expensive.